Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gyre Therapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with U.S. and China operations, revenue from Gyre Pharmaceuticals, and a pipeline centered on anti-fibrotic therapies and targeted protein degradation assets. Form 8-K reports cover operating results, business updates, CDE/NMPA regulatory disclosures for F351, and clinical-program updates for Hydronidone and pirfenidone.
Proxy and material-event filings describe governance matters, shareholder voting items, material agreements, capital-structure disclosures and the completed Cullgen acquisition, including preferred-stock and common-stock conversion mechanics. The record also includes Regulation FD disclosures addressing commercial products, research spending and pipeline development.
GYRE THERAPEUTICS, INC. Chief Operating Officer Ye Weiguo reported option exercises and related share sales. He exercised stock options covering 22,220 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions.
The common stock sales on May 20 and May 21, 2026 were executed at a weighted average price of $6.15 per share, with actual sale prices ranging from about $6.05 to $6.29 according to the footnotes. After these transactions, Ye directly owns 700,000 shares of GYRE common stock.
GYRE Therapeutics director Zhang Ping reported a cancellation of stock options previously granted by the company. A stock option covering 250,000 shares of common stock with a $10.18 exercise price and a May 27, 2035 expiration was disposed of back to the issuer.
According to the disclosure, the option was canceled by mutual agreement, and the company will provide consideration whose form and amount it will determine, but this consideration will not have economic value. The canceled grant would have begun vesting on May 27, 2026, with monthly vesting over three additional years, and no shares remain from this option after the transaction.
GYRE Therapeutics Chief Operating Officer Ye Weiguo reported a small exercise-and-sell sequence in common stock. On May 18–19, he exercised stock options covering 9,320 shares of common stock at an exercise price of $0.75 per share and sold the same number of shares in open-market transactions at weighted average prices around $6.37 per share, within disclosed price ranges. Following these transactions, he directly holds 700,000 shares of common stock.
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a small exercise-and-sell pattern over two days. On May 14 and 15, 2026, he exercised stock options to acquire a total of 28,680 shares of common stock at $0.75 per share and sold the same number of shares in open-market transactions, at weighted average prices of $6.91 and $6.65, respectively, across multiple trades.
After these transactions, Ye directly owns 700,000 shares of common stock. All options involved were fully vested, and the sales were executed across price ranges disclosed through weighted-average pricing footnotes.
Gyre Therapeutics, Inc. furnished a scientific presentation it will deliver at a conference in Shanghai, outlining its strategy as a fully integrated biopharmaceutical company focused on fibrosis, inflammatory diseases and cancer, including the recently announced acquisition of Cullgen.
The presentation highlights a broad pipeline from discovery to marketed products and a global footprint with headquarters in San Diego and major discovery, development, manufacturing and commercial operations in China. Gyre reports about 740 employees worldwide across R&D, manufacturing, sales and marketing, and G&A functions.
A key focus is CG923308, a CDK2/cyclin E degrader for CCNE1-amplified solid tumors and HR+/HER2- breast cancer resistant to CDK4/6 inhibitors. Preclinical data show potent, selective protein degradation, oral bioavailability in multiple species, strong in vitro and in vivo anti-cancer activity versus Phase 2/3 CDK2 inhibitors, and tolerability in animal models. Cullgen anticipates submitting an Investigational New Drug application for CG923308 in the first quarter of 2027. The presentation is furnished as Exhibit 99.1 under Item 7.01 and is not deemed filed under the Exchange Act.
Gyre Therapeutics, Inc. announced that China’s National Medical Products Administration, through its Center for Drug Evaluation, has accepted a New Drug Application for F351 (hydronidone) to treat chronic hepatitis B-induced liver fibrosis. The NDA was submitted via its majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd., and follows the product’s earlier priority review status. F351 is Gyre’s lead liver fibrosis candidate and has also been developed for MASH-associated liver fibrosis, with plans to file a U.S. IND by the end of 2026.
Gyre Therapeutics, Inc. reported Q1 2026 revenue of $22.5 million, slightly above $22.1 million a year earlier, driven mainly by ETUARY, which contributed $21.0 million, or 93.1% of product sales. Newer products Contiva and Etorel added modest but growing contributions.
The company posted a net loss of $9.9 million, compared with net income of $3.7 million in Q1 2025, as selling, R&D, G&A and $2.6 million of transaction costs lifted operating expenses to $31.9 million. Despite the loss, operating cash flow was positive at $3.2 million, and cash and cash equivalents were $37.5 million as of March 31, 2026.
Total assets were $162.0 million and equity $137.0 million. Gyre’s China subsidiary remained the sole revenue source, while U.S. operations focused on Hydronidone development. After quarter-end, Gyre closed an all‑stock acquisition of Cullgen valued at approximately $300 million, bringing a new pipeline under common control accounting.
GYRE Therapeutics, Inc. Chief Executive Officer Luo Ying reported indirect open-market sales of company common stock held by a spouse. On May 5–6, 2026, a total of 10,315 shares of common stock were sold in two transactions at weighted average prices of $8.01 and $8.04 per share. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025, indicating they were pre-arranged. Following these transactions, indirect holdings reported as owned through the spouse totaled 2,565,226 shares of common stock.
Gyre Therapeutics, Inc. executive Joshua Benjamin Bergmann, the company’s GC and Corporate Secretary, reported his initial ownership of a stock option in a Form 3 filing. The option gives him the right to buy 47,530 shares of common stock at an exercise price of $8.09 per share.
According to the filing, the option expires on February 27, 2036. One quarter of the option will vest on June 16, 2026, and the remaining three quarters will vest in equal monthly installments over the following three years, as long as he continues serving the company on each vesting date.